Mechanisms of the anti-inflammatory actions of the angiotensin type1 receptor antagonist losartan in experimental models of arthritis

Peptides

Volumn 46, Issue , 2013, Pages 53-63

  Silveira, Kátia D ^a   Coelho, Fernanda M ^a   Vieira, Angélica T ^a   Barroso, Lívia C ^a   Queiroz, Celso M ^a,b   Costa, Vívian V ^a   Sousa, Larissa F C ^a   Oliveira, Marilene L ^a   Bader, Michael ^d   Silva, Tarcíla A ^a,b   Santos, Robson A S ^a   Simões E Silva, Ana Cristina ^c   Teixeira, Mauro M ^a  

^a Institute of Biological Sciences   (Brazil)

^b Dental School   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Arthritis; Cytokines; Hypernociception; Inflammation; Leukocytes; Losartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANTIGEN; CXCL1 CHEMOKINE; INTERLEUKIN 1BETA; LOSARTAN; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN INDUCED ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CARTILAGE MATRIX; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; JOINT CAVITY; JOINT INJURY; LEUKOCYTE; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TISSUE INJURY;

ADIA; ANIMALIA; MUS; RATTUS;

ARTHRITIS; CYTOKINES; HYPERNOCICEPTION; INFLAMMATION; LEUKOCYTES; LOSARTAN;

ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL ADHESION; CHEMOKINE CXCL1; DISEASE MODELS, ANIMAL; FEMALE; HYPERALGESIA; INFLAMMATION; INTERLEUKIN-1BETA; LEUKOCYTE ROLLING; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879205322     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.05.012     Document Type: Article

References (51)

1. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol CellPhysiol 2004;286:C779-84.
2. Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, Rachid M, et al. Renopro-tective effects of AVE0991, a nonpeptide Mas receptor agonist, in experimentalacute renal injury. Int J Hypertens 2012:2012.
3. Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 2005;516:282-9.
4. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in thetreatment of arthritis. Best Pract Res Clin Rheumatol 2006;20:879-96.
5. Coelho FM, Pinho V, Amaral FA, Sachs D, Costa VV, Rodrigues DH, et al. Thechemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis byregulating adhesion of neutrophils to the synovial microvasculature. ArthritisRheum 2008;58:2329-37.
6. Cunha TM, Verri Jr WA, Silva JS, Poole S, Cunha FQ, Ferreira SH. A cascade ofcytokines mediates mechanical inflammatory hypernociception in mice. ProcNatl Acad Sci U S A 2005;102:1755-60.
7. Cunha TM, Verri Jr WA, Valerio DA, Guerrero AT, Nogueira LG, Vieira SM, et al.Role of cytokines in mediating mechanical hypernociception in a model ofdelayed-type hypersensitivity in mice. Eur J Pain 2008;12:1059-68.
8. Cunha TM, Verri Jr WA, Vivancos GG, Moreira IF, Reis S, Parada CA, et al. Anelectronic pressure-meter nociception paw test for mice. Braz J Med Biol Res2004;37:401-7.
9. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis.Rheumatology (Oxford) 2005;44:24-31.
10. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis.Annu Rev Immunol 1996;14:397-440.
11. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E,et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7)forming enzymes and receptors. Kidney Int 2005;68:2189-96.
12. Figueroa JE, Vijayagopal P. Angiotensin II stimulates synthesis of vascularsmooth muscle cell proteoglycans with enhanced low density lipoprotein bind-ing properties. Atherosclerosis 2002;162:261-8.
13. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature2003;423:356-61.
14. Grespan R, Fukada SY, Lemos HP, Vieira SM, Napimoga MH, Teixeira MM, et al.CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment ofneutrophils to inflamed joints in mice with antigen-induced arthritis. ArthritisRheum 2008;58:2030-40.
15. Guerrero AT, Verri Jr WA, Cunha TM, Silva TA, Schivo IR, Dal-Secco D, et al.Involvement of LTB4 in zymosan-induced joint nociception in mice: participa-tion of neutrophils and PGE2. J Leukoc Biol 2008;83:122-30.
16. Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is alreadyexpensive during the first year of the disease (the Swedish TIRA project).Rheumatology (Oxford) 2004;43:1374-82.
17. Hanafy S, Dagenais NJ, Dryden WF, Jamali F. Effects of angiotensin II blockadeon inflammation-induced alterations of pharmacokinetics and pharmacody-namics of calcium channel blockers. Br J Pharmacol 2008;153:90-9.
18. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM.Upregulation of angiotensin-converting enzyme 2 after myocardial infarctionby blockade of angiotensin II receptors. Hypertension 2004;43:970-6.
19. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihy-pertensive effects of blockade of the renin-angiotensin system. Hypertension1998;31:356-61.
20. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A mul-ticenter, double-blind, dose-ranging, randomized, placebo-controlled studyof recombinant human interleukin-1 receptor antagonist in patients withrheumatoid arthritis: radiologic progression and correlation of Genant andLarsen scores. Arthritis Rheum 2000;43:1001-9.
21. Kawakami Y, Matsuo K, Murata M, Yudoh K, Nakamura H, Shimizu H, et al.Expression of angiotensin II receptor-1 in human articular chondrocytes.Arthritis 2012;2012:648537.
22. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computer-ized tail-cuff system for measuring blood pressure in mice. Hypertension1995;25:1111- 5.
23. Lapteva N, Nieda M, Ando Y, Ide K, Hatta-Ohashi Y, Dymshits G, et al. Expres-sion of renin-angiotensin system genes in immature and mature dendriticcells identified using human cDNA microarray. Biochem Biophys Res Commun2001;285:1059-65.
24. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al.Infections in patients with rheumatoid arthritis treated with biologic agents.Arthritis Rheum 2005;52:3403-12.
25. Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerda-Nicolas M, Proudfoot AE,et al. Angiotensin II-induced mononuclear leukocyte interactions with arte-riolar and venular endothelium are mediated by the release of different CCchemokines. J Immunol 2006;176:5577-86.
26. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM,Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinanthuman tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med1997;337:141-7.
27. Nabah AYN, Losada M, Estelles R, Mateo T, Company C, Piqueras L, et al.CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis andmononuclear leukocyte infiltration. Arterioscler Thromb Vasc Biol 2007;27:2370-6.
28. Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, et al. AngiotensinII induces neutrophil accumulation in vivo through generation and release ofCXC chemokines. Circulation 2004;110:3581-6.
29. Nagy N, Melchior-Becker A, Fischer JW. Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murineatherosclerosis. Basic Res Cardiol 2010;105:29-38.
30. Passos GF, Fernandes ES, Campos MM, Araujo JG, Pesquero JL, Souza GE,et al. Kinin B1 receptor up-regulation after lipopolysaccharide administra-tion: role of proinflammatory cytokines and neutrophil influx. J Immunol2004;172:1839- 47.
31. Price A, Lockhart JC, Ferrell WR, Gsell W, McLean S, Sturrock RD. AngiotensinII type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivoanalyses in rodent models of arthritis and ex vivo analyses in human inflam-matory synovitis. Arthritis Rheum 2007;56:441-7.
32. Pueyo ME, Michel JB. Angiotensin II receptors in endothelial cells. Gen Pharma-col 1997;29:691-6.
33. Refaat R, Salama M, Abdel Meguid E, El Sarha A, Gowayed M. Evaluation of theeffect of losartan and methotrexate combined therapy in adjuvant- inducedarthritis in rats. Eur J Pharmacol 2013;698:421-8.
34. Rose JM, Audus KL. AT1 receptors mediate angiotensin II uptake and transportby bovine brain microvessel endothelial cells in primary culture. J CardiovascPharmacol 1999;33:30-5.
35. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin IIactivates nuclear transcription factor kappaB through AT(1) and AT(2) in vas-cular smooth muscle cells: molecular mechanisms. Circ Res 2000;86:1266-72.
36. Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Angiotensin Egido J. II acti-vates nuclear transcription factor-kappaB in aorta of normal rats and invascular smooth muscle cells of AT1 knockout mice. Nephrol Dial Transplant2001;16(Suppl 1):27-33.
37. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatoryactions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-9.
38. Sachs D, Coelho FM, Costa VV, Lopes F, Pinho V, Amaral FA, et al. Cooperative roleof tumour necrosis factor-alpha, interleukin-1beta and neutrophils in a novelbehavioural model that concomitantly demonstrates articular inflammationand hypernociception in mice. Br J Pharmacol 2011;162:72-83.
39. Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor block-ers suppress antigen-specific T cell responses and ameliorate collagen-inducedarthritis in mice. Arthritis Rheum 2005;52:1920-8.
40. Santos RA, Ferreira AJ, Simoes e Silva AC. Recent advances in theangiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol2008;93:519-27.
41. Shimizu-Hirota R, Sasamura H, Mifune M, Nakaya H, Kuroda M, Hayashi M, et al.Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type2 receptors. J Am Soc Nephrol 2001;12:2609-15.
42. Silveira KD, Coelho FM, Vieia AT, Sachs D, Barroso LC, Costa VV, et al. Anti-inflammatory effects of the activation of the Angiotensin-(1-7) receptor, Mas,in experimental models of arthritis. J Immunol 2010;185:5569-76.
43. Silveira KD, Santos RAS, Barroso LC, Lima CX, Teixeira MM, Simoes Silva AC. Theadministration of the agonist of angiotensin-(1-7), AVE0991, improved inflam-mation and proteinuria in experimental nephrotic syndrome. 15th Congress ofthe International Pediatric Nephrology Association, vol. 25. Pediatr Nephrol2010:1779-2004.
44. Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, MaM, et al. Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas recep-tor in rats with dilated cardiomyopathy induced by experimental autoimmunemyocarditis. Life Sci 2012;90:289-300.
45. Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, MaM, et al. Cardioprotective effects of telmisartan against heart failure in ratsinduced by experimental autoimmune myocarditis through the modulation ofangiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J BiolSci 2011;7:1077-92.
46. Takemori K, Ito H, Suzuki T. Effects of the AT1 receptor antagonist on adhe-sion molecule expression in leukocytes and brain microvessels of stroke-pronespontaneously hypertensive rats. Am J Hypertens 2000;13:1233-41.
47. Urech DM, Feige U, Ewert S, Schlosser V, Ottiger M, Polzer K, et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injectedanti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local thera-peutic use. Ann Rheum Dis 2010;69:443-9.
48. Veale D, Yanni G, Bresnihan B, FitzGerald O. Production of angiotensinconverting enzyme by rheumatoid synovial membrane. Ann Rheum Dis1992;51:476-80.
49. Veihelmann A, Szczesny G, Nolte D, Krombach F, Refior HJ, Messmer K. A novelmodel for the study of synovial microcirculation in the mouse knee joint invivo. Res Exp Med (Berl) 1998;198:43-54.
50. Walsh DA, Suzuki T, Knock GA, Blake DR, Polak JM, Wharton J. AT1 recep-tor characteristics of angiotensin analogue binding in human synovium. Br JPharmacol 1994;112:435-42.
51. Williams AS, Richards PJ, Thomas E, Carty S, Nowell MA, Goodfellow RM, et al.Interferon-gamma protects against the development of structural damage inexperimental arthritis by regulating polymorphonuclear neutrophil influx intodiseased joints. Arthritis Rheum 2007;56:2244-54.